Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
TRATAMIENTO ADYUVANTE CANCER COLON LOCALMENTE AVANZANDO EVALUACION CANDIDATOS A TRATAMIENTO PRINCIPIOS TERAPIA ADYUVANTE 6 MESES 4.2% FOLFOX VS XELOX Seven-year DFS rates were 63% and 56% in the XELOX and FU/FA groups, respectively (hazard ratio [HR], 0.80; 95% CI, 0.69 to 0.93; P = .004). Seven-year OS rates were 73% and 67% in the XELOX and FU/FA groups, respectively (HR, 0.83; 95% CI, 0.70 to 0.99; P = .04). OS at 10 years for N1 EC III tumors was 65.4% (95% CI, 62.8% to 68%) in the LV5FU2 arm and was 71.4% (95% CI, 69.1% to 73.7%) in the FOLFOX4 arm (HR, 0.86; 95% CI, 0.67 to 1.11; P .248 for N2 EC III tumors, OS at 10 years was 46.6% (95% CI, 43.2% to 50%) in the LV5FU2 arm and was 59.5% (95% CI, 56.1% to 62.9%) in the FOLFOX4 arm (HR, 0.70; 95% CI, 0.53 to 0.93; P .013; BENEFICIO SG NO SIGNIFC TERAPIA BLANCO CONCLUSIONES • QT ADYUVANTE ES INDICADO PARA ECIII (N+) FOLFOX / CapeOx Capecitabine or (inf.) FU/LV (ALGUNOS PCTES ) , FOLFOX / CapeOx PARA pts < 70a • La decision de qt adyuvante debe tener en cuenta el balance de riesgo y comorbilidades. MENSAJES PARA LA CASA